Chemo Drug Improves Survival after Pancreatic Cancer Surgery
(Ivanhoe Newswire) –New research suggests that among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for six months resulted in increased overall survival and disease-free survival, compared with the observation alone.
The study at Charite-Universitatsmedizin Berlin, Germany, and colleagues conducted follow-up of a randomized trial that previously reported improvement in disease-free survival with adjuvant gemcitabine therapy to determine if this treatment improved overall survival. By the end of the follow-up period, 89.3 percent of patients had died. The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.
“[These] data show that among patients with macroscopic complete removal of pancreatic cancer, the use of adjuvant gemcitabine for 6 months compared with observation resulted in increased overall survival as well as disease-free survival. These findings support the use of gemcitabine in this setting,” Helmut Oettle, M.D., Ph.D, and colleagues were quoted as saying.
For more information, go to: http://media.jamanetwork.com/news-item/chemotherapy-drug-improves-survival-following-surgery-pancreatic-cancer/
SOURCE: JAMA, October 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.